|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined changes in CTC numbers and morphology early after targeting therapy in EGFR-mutated PC-9 human lung cancer and HER2-gene amplified GLM-1 gastric cancer mouse CTC models using a cytology-based semi-automated CTC detection platform.
|
31519570 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer patients.
|
31132309 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because of the specific characteristics of Chinese patients with lung cancer (such as high epidermal growth factor receptor mutation rates, later disease stages, and different toxicity profiles), large-scale clinical trials targeting the Chinese population or Chinese participation in multinational trials should be promoted.
|
30819828 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this review is to: 1) analyze various preanalytical, analytical, and postanalytical factors influencing ICC results; 2) discuss measures for validation of ICC protocols; and 3) summarize published data on predictive ICC for ALK, ROS1, EGFR gene alterations and PD-L1 expression on lung cancer cytology.
|
31050216 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Alterations hypothesized to confer AR were introduced into drug-sensitive EGFR-mutant lung cancer cell lines (H1975, HCC827, and PC9) by using clustered regularly interspaced short palindromic repeats/Cas9 genome editing.
|
30831205 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Six human lung cancer cell lines with wild-type or mutant EGFR gene were exposed to pemetrexed and icotinib combined in different sequences.
|
30953548 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
|
30835140 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
SIGNIFICANCE: The clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in <i>EGFR</i>-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.
|
31092401 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the epidermal growth factor receptor (EGFR) mutation status of samples of lung cancer patients stored before introduction of the plasma EGFR test at our institution.
|
30888199 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i>-Mutant Lung Cancers.
|
31320402 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, dual inhibition of COX-2 and EGFR by melafolone improves checkpoint blockade therapy through vascular normalization and PD-L1 downregulation and, by affecting vessels and immune cells, may be a promising combination strategy for the treatment of human lung cancer.
|
30591531 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
3D-organotypic invasion assays reveal that CCB02 has broad anti-invasive activity in various cancer models, including tyrosine kinase inhibitor (TKI)-resistant EGFR-mutant non-small-cell lung cancers.
|
30530478 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
|
31377341 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations.
|
31378236 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Protein tyrosine kinase 2 (PTK2) expression has been reported in various types of human epithelial cancers including lung cancer; however, the role of PTK2 in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) has not been elucidated.
|
31791326 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples.
|
30799393 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the molecular mechanisms underlying the effects of this medicine, particularly to enhance the efficiency of EGFR-TKI in the treatment of lung cancer have not been well elucidated.
|
30910577 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
EGFR TKI-resistant lung cancers often remain sensitive to inhibition of the EGFR pathway; thus, c-MET inhibitors are likely to be effective when combined with continued EGFR-TKI treatment.
|
30422759 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Importantly, CAP combining with iron oxide-based MNPs induced EGFR downregulation while CAP inhibited lung cancer cells via depressing pERK and pAKT.
|
30342190 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that KCNK15-AS1 functions as an oncogene via regulating the miR-202/miR-370/EGFR axis in lung cancer and may provide a potential target for lung cancer treatment.
|
31788071 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
BBI608, a STAT3 inhibitor, was a potential therapeutic agent that reduced the cell viability of EGFR-positive lung cancer cell lines.
|
31619200 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.
|
30868686 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Enzyme-linked immunosorbent assay (ELISA) was performed to detect the EGFR-reactive IgG in lung cancer patients.
|
31722672 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
From transcriptomics data mining, we found that coordination between BZW1 and EGFR overexpression was correlated with a worse outcome for lung cancer patients.
|
31601833 |
2019 |
|
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
|
30797494 |
2019 |